Roy A.  Jensen, MD

Roy A. Jensen, MD

University of Kansas Cancer Center

Director at The University of Kansas Cancer Center and Director at Kansas Masonic Research Institute (KMCRI)

Expertise: PathologyLaboratory MedicineAnatomyCell Biology

Roy A. Jensen, M.D. earned his bachelor’s degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource.  Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001.

In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer.

Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.

Roy Jensen, M.D., director of The University of Kansas Cancer Center, has been named president of the Association of American Cancer Institutes (AACI), an organization of 98 leading academic cancer centers in North America, which includes the 70 National

Dr. Roy Jensen, M.D., says the dramatic impact the pandemic has had on cancer patients across the nation. He says that because many screenings have been delayed.

that advice sounds very similar to what we’re giving to the general public. I’m sure that one of the specific questions that cancer patient has is around their appointments and coming in to see the physicians.

No Research/Citations

Cancer Center Receives Additional $5 Million in Funding from State of Kansas to Support Ongoing Research

The University of Kansas Cancer Center will receive an additional $5 million from the state budget for the KU Cancer Center Research Fund.
31-Mar-2020 05:15:24 PM EDT

"In addition to offering treatment, the new center will offer opportunities to continue research on proton therapy for new and expanded uses in the future,"

- Region's First Proton Therapy Cancer Treatment Coming to The University of Kansas Health System

“Essentially, the infrastructure that you have to put in place to monitor that is not worth the bang for the buck,” said Dr. Roy Jensen, the director of the University of Kansas Cancer Center."

- Plan for work requirement is focus of Kansas Medicaid debate

“We have not seen any transmission of the virus to any of our healthcare workers. We have started a program of voluntary testing for COVID among our faculty and staff to assure our patients that our workforce is safe, and this is a safe environment.”

- Cancer Docs Join Fight Against COVID: Live Event

“African American populations, Hispanic populations, folks in lower socioeconomic status and high levels of chronic disease were significantly greater impacted by this virus than other groups.”

- Cancer Docs Join Fight Against COVID: Live Event

Available for logged-in users onlyLogin HereorRegister